Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update

Simple item page
dc.contributor.authorLoprinzi, Charles L.
dc.contributor.authorLacchetti, Christina
dc.contributor.authorBleeker, Jonathan
dc.contributor.authorCavaletti, Guido
dc.contributor.authorChauhan, Cynthia
dc.contributor.authorHertz, Daniel L.
dc.contributor.authorKelley, Mark R.
dc.contributor.authorLavino, Antoinette
dc.contributor.authorLustberg, Maryam B.
dc.contributor.authorPaice, Judith A.
dc.contributor.authorSchneider, Bryan P.
dc.contributor.authorLavoie Smith, Ellen M.
dc.contributor.authorSmith, Mary Lou
dc.contributor.authorSmith, Thomas J.
dc.contributor.authorWagner Johnston, Nina
dc.contributor.authorHershman, Dawn L.
dc.contributor.departmentPediatrics, School of Medicineen_US
dc.date.accessioned2022-01-13T20:37:17Z
dc.date.available2022-01-13T20:37:17Z
dc.date.issued2020-10
dc.description.abstractPURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationLoprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology, 38(28), 3325–3348. https://doi.org/10.1200/JCO.20.01399en_US
dc.identifier.urihttps://hdl.handle.net/1805/27436
dc.language.isoenen_US
dc.publisherASCOen_US
dc.relation.isversionof10.1200/JCO.20.01399en_US
dc.relation.journalJournal of Clinical Oncologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePublisheren_US
dc.subjectchemotherapy-induced peripheral neuropathyen_US
dc.subjectadult cancer survivorsen_US
dc.subjectpreventionen_US
dc.titlePrevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Updateen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Loprinzi2020Prevention.pdf
Size:
2.52 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Pediatrics Works
Mark R. Kelley